The study aimed to describe clinical characteristics, risk factors, histopathologic and immunologic features of systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD).
The study evaluated IL-18 levels in systemic juvenile idiopathic arthritis by assessing disease activity, history of macrophage activation syndrome, and other disease biomarkers.
Investigators assessed the real-world efficacy of simple strategies to treat juvenile idiopathic arthritis as current guidelines recommend.
CDC investigators assessed recent state-specific data on the prevalence of arthritis and, in doing so, observed an association between severe joint pain and physical inactivity in adults with arthritis.
The American College of Rheumatology and the Arthritis Foundation have released updated recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis with associated uveitis.
The American College of Rheumatology and Arthritis Foundation have released updated guidelines for management of non-systemic polyarthritis, sacroiliitis, and enthesitis in patients with juvenile idiopathic arthritis.
Patients with JIA who received tocilizumab therapy experienced transient neutropenia that was not associated with an increased number of infections.
Although there was high agreement and similar classification of change among the questionnaires, these may not be completely interchangeable.
Data show that more than half of patients with juvenile idiopathic arthritis were no longer on methotrexate therapy.
An algorithm that can classify patients with juvenile idiopathic arthritis (JIA) into seven distinct groups based on patterns of swollen or painful joints in the body can help predict disease course.
